Behçet disease (CNS manifestations)
Updates to Article Attributes
CNS manifestations of Behçet disease (or, also known as neuro-Behçet disease) is one of the more, correspond to a common manifestations ofinvolvement related to systemicBehçet disease and has a variety of manifestations.
For a discussion of the disease in general please refer to Behçet disease article.
Epidemiology
CNS involvement is seen in 4-49% of patients with systemic Behçet disease, and has the same predilection of patients of middle eastern and Japanese descent 1.
Clinical presentation
In the vast majority of cases, ulcerative lesions preceded neurological involvement, aiding in the diagnosis. In 3% of cases central nervous system manifestations occur first, making diagnosis significantly more challenging 1. Signs and symtomssymptoms include 1:
- headaches
- sensory disturbances
- personality changes
- dysarthria
- cerebellar signs
Pathology
Neuro-Behçet disease, depending on the stage or degree of the inflammation, shows a perivascular infiltration of leukocytes and microglia, degeneration of oligodendroglia, and perivascular softening or necrosis 3.
Radiographic features
Unfortunately, neuro-Behçet disease has a wide variety of manifestations in the central nervous system, including 1:
- focal or multifocal lesions
- meningoencephalitis
- cerebral vein thrombosis
Meningoencephalitis and cerebral vein thrombosis are are discussed separately in general articles related to these conditions.
MRI
Neuro: Behçet disease typically involves 1,3, in order of preference:
- brainstem: most common
- basal ganglia: bilateral in a third of cases
brainstem- thalamus
- subcortical white matter: less common
- spinal cord: less common
Lesions of Behçet disease typically demonstrate the following signal characteristics 1:
- T1: usually hypo-intense
-
T2
:- usually hyperintense
- associated with vasogenic oedema
- in acute phase lesions cause mass effect
- T1 C+ (Gd): typically moderate patchy enhancement
- DWI: isointense to slightly hyperintense [Ed: T2 shine through or true restricted diffusion?]
Treatment and prognosis
- corticosteroids: i.v.
methlyprednisolonemethylprednisolone infusion then oral prednisone - immunosuppression: azathioprine, methotrexate, and anti TNFα 2
Differential diagnosis
- multiple sclerosis
- sarcoidosis
- primary lymphoma
- gliomatosis cerebri
- antiphospholipid syndrome
- Sweet syndrome
Consider other causes of T2 hyperintensity of the basal ganglia.
-<p><strong>CNS manifestations of Behçet</strong> <strong>disease</strong> (or <strong>neuro-Behçet disease</strong>) is one of the more common manifestations of systemic<a href="/articles/behcet-disease-2"> Behçet disease </a>and has a variety of manifestations. </p><p>For a discussion of the disease in general please refer to<a href="/articles/behcet-disease-2"> Behçet disease </a>article. </p><h4>Epidemiology</h4><p>CNS involvement is seen in 4-49% of patients with systemic <a href="/articles/behcet-disease-2">Behçet disease</a>, and has the same predilection of patients of middle eastern and Japanese descent <sup>1</sup>. </p><h4>Clinical presentation</h4><p>In the vast majority of cases, ulcerative lesions preceded neurological involvement, aiding in the diagnosis. In 3% of cases central nervous system manifestations occur first, making diagnosis significantly more challenging <sup>1</sup>. Signs and symtoms include <sup>1</sup>:</p><ul>- +<p><strong>CNS manifestations of Behçet</strong> <strong>disease</strong>, also known as <strong>neuro-Behçet disease</strong>, correspond to a common involvement related to systemic <a href="/articles/behcet-disease-2">Behçet disease</a> and has a variety of manifestations. </p><p>For a discussion of the disease in general please refer to<a href="/articles/behcet-disease-2"> Behçet disease </a>article. </p><h4>Epidemiology</h4><p>CNS involvement is seen in 4-49% of patients with systemic <a href="/articles/behcet-disease-2">Behçet disease</a>, and has the same predilection of patients of middle eastern and Japanese descent <sup>1</sup>. </p><h4>Clinical presentation</h4><p>In the vast majority of cases, ulcerative lesions preceded neurological involvement, aiding in the diagnosis. In 3% of cases central nervous system manifestations occur first, making diagnosis significantly more challenging <sup>1</sup>. Signs and symptoms include <sup>1</sup>:</p><ul>
-</ul><h4>Radiographic features</h4><p>Unfortunately, neuro-Behçet disease has a wide variety of manifestations in the central nervous system, including <sup>1</sup>: </p><ul>- +</ul><h4>Pathology</h4><p>Neuro-Behçet disease, depending on the stage or degree of the inflammation, shows a perivascular infiltration of leukocytes and microglia, degeneration of oligodendroglia, and perivascular softening or necrosis <sup>3</sup>.</p><h4>Radiographic features</h4><p>Unfortunately, neuro-Behçet disease has a wide variety of manifestations in the central nervous system, including <sup>1</sup>: </p><ul>
-</ul><p>Meningoencephalitis and cerebral vein thrombosis are discussed separately. </p><h5>MRI</h5><p>Neuro: Behçet disease typically involves <sup>1</sup>: </p><ul>- +</ul><p>Meningoencephalitis and cerebral vein thrombosis are discussed separately in general articles related to these conditions. </p><h5>MRI</h5><p>Neuro: Behçet disease typically involves <sup>1,3</sup>, in order of preference: </p><ul>
- +<li>brainstem: most common</li>
-<li>brainstem</li>-<li>thalamus</li>- +<li><span style="line-height:1.6">thalamus</span></li>
-<strong>T2:</strong><ul>- +<strong>T2</strong><ul>
-<li>corticosteroids: i.v. methlyprednisolone infusion then oral prednisone </li>- +<li>corticosteroids: i.v. methylprednisolone infusion then oral prednisone </li>
-</ul><p> </p><h4>Differential diagnosis</h4><ul>- +</ul><h4>Differential diagnosis</h4><ul>
References changed:
- 3. Matsuo K, Yamada K, Nakajima K, Nakagawa M. Neuro-Behçet Disease Mimicking Brain Tumor. AJNR Am J Neuroradiol. 2005;26(3):650-3. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7976491">PMC7976491</a> - <a href="https://www.ncbi.nlm.nih.gov/pubmed/15760881">Pubmed</a>